Exposure to myeloma cell lysates affects the immune competence of dendritic cells and favors the induction of Tr1-like regulatory T cells

European Journal of Immunology

Volumn 35, Issue 4, 2005, Pages 1155-1163

  Fiore, Francesca ^a,b   Nuschak, Barbara ^a,b   Peola, Silvia ^a,b   Mariani, Sara ^a,b   Muraro, Michela ^a,b   Foglietta, Myriam ^a,b   Coscia, Marta ^a,b   Bruno, Benedetto ^a   Boccadoro, Mario ^a   Massaia, Massimo ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

Anti tumor immunity; Dendritic cells; Myeloma; Tumor lysates

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4;

ARTICLE; CELL DEATH; CELL INTERACTION; CELL LYSATE; CELL MATURATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DATA ANALYSIS; DENDRITIC CELL; HOST; HUMAN; HUMAN CELL; IMMUNITY; IMMUNOCOMPETENCE; INTERNALIZATION; LYMPHOCYTE PROLIFERATION; MULTIPLE MYELOMA; MYELOMA CELL; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR CELL; TUMOR CELL LINE;

CELL DIFFERENTIATION; CELL EXTRACTS; DENDRITIC CELLS; HUMANS; MULTIPLE MYELOMA; T-LYMPHOCYTES;

EID: 20244386558     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200425093     Document Type: Article

References (39)

1. Corradini, P., Voena, C., Astolfi, M., Ladetto, M., Tarella, C., Boccadoro, M. and Pileri, A., High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood 1995. 85: 1596-1602.
2. Shtill, A. A., Turner, J. G., Durfee, J., Dalton, W. S. and Yu, H., Cytokine-based tumor cell vaccine is equally effective against parental and isogenic multidrug-resistant myeloma cells: the role of cytotoxic T lymphocytes. Blood 1999. 93: 1831-1837.
3. Lokhorst, H. M., Schattenberg, A., Cornelissen, J. J., van Oers, M. H., Fibbe, W., Russell, I., Donk, N. W. and Verdonck, L. F., Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J. Clin. Oncol. 2000. 18: 3031-3037.
4. Cavo, M., Terragna, C., Martinelli, G., Ronconi, S., Zamagni, E., Tosi, P., Lemoli, R. M., Benni, M., Pagliani, G., Bandini, G. and Tura, S., Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood 2000. 96: 355-357.
5. Massaia, M., Borrione, P., Battaglio, S., Mariani, S., Beggiato, E., Napoli, P., Voena, C., Bianchi, A., Coscia, M., Besostri, B. et al., Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood 1999. 94: 673-683.
6. Coscia, M., Mariani, S., Battaglio, S., Di Bello, C., Fiore, F., Foglietta, M., Pileri, A., Boccadoro, M. and Massaia, M., Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. Leukemia 2004. 18: 139-145.
7. Banchereau, J., Schuler-Thurner, B., Palucka, A. K. and Schuler, G., Dendritic cells as vectors for therapy. Cell 2001. 106: 271-274.
8. Liu, Y. J., Kanzler, H., Soumelis, V. and Gilliet, M., Dendritic cell lineage, plasticity and cross-regulation. Nat. Immunol. 2001. 2: 585-589.
9. Reichardt, V. L., Okada, C. Y., Liso, A., Benike, C. J., Stockerl-Goldstein, K. E., Engleman, E. G., Blume, K. G. and Levy, R., Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-a feasibility study. Blood 1999. 93: 2411-2419.
10. van Baren, N., Brasseur, F., Godelaine, D., Hames, G., Ferrant, A., Lehmann, F., Andre, M., Ravoet, C., Doyen, C., Spagnoli, G. C. et al., Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood 1999. 94: 1156-1164.
11. Gallucci, S., Lolkema, M. and Matzinger, P., Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 1999. 5: 1249-1255.
12. Sauter, B., Albert, M. L., Francisco, L., Larsson, M., Somersan, S. and Bhardwaj, N., Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med. 2000. 191: 423-434.
13. Pfeiffer, S., Gooding, R. P., Apperley, J. F., Goldschmidt, H. and Samson, D., Dendritic cells generated from the blood of patients with multiple myeloma are phenotypically and functionally identical to those similarly produced from healthy donors. Br. J. Haematol. 1997. 98: 973-982.
14. + T cell priming by dendritic cells in intact lymph nodes. Nat. Immunol. 2003. 4: 579-585.
15. Boonstra, A., Asselin-Paturel, C., Gilliet, M., Crain, C., Trinchieri, G., Liu, Y.-J. and O'Garra, A., Flexibility of mouse classical and plasmacytoid-derived dendritic cells in directing T helper type 1 and 2 cell development: dependency on antigen dose and differential Toll-like receptor ligation. J. Exp. Med. 2003. 197: 101-109.
16. Feng, H., Zeng, Y., Whitesell, L. and Katsanis, E., Stressed apoptotic tumor cells express hear shock proteins and elicit tumor-specific immunity. Blood 2001. 97: 3505-3512.
17. Matzinger, P., The danger model: a renewed sense of self. Science 2002. 296: 301-305.
18. Somersan, S., Larsson, M., Fonteneau, J. F., Basu, S., Srivastava, P. and Bhardwaj, N., Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells. J. Immunol. 2001. 167: 4844-4852.
19. Bausinger, H., Lipsker, D., Ziylan, U., Manie, S., Briand, J. P., Cazenave, J. P., Muller, S., Haeuw, J. F., Ravanat, C., de la Salle, H. and Hanau, D., Endotoxin-free heat-shock protein 70 fails to induce APC activation. Eur. J. Immunol. 2002. 32: 3708-3713.
20. Bethke, K., Staib, F., Distler, M., Schmitt, U., Jonuleit, H., Enk, A. H., Galle, P. R. and Heike, M., Different efficiency of heat shock proteins (HSP) to activate human monocytes and dendritic cells: superiority of HSP60. J. Immunol. 2002. 169: 6141-6148.
21. + T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J. Exp. Med. 2000. 192: 1213-1222.
22. Steinman, R. M., Hawiger, D., Liu, K., Bonifaz, L., Bonnyay, D., Mahnke, K., Iyoda, T., Ravetch, J., Dhodapkar, M., Inaba, K. and Nussenzweig, M., Dendritic cell function in vivo during the steady state: A role in peripheral tolerance. Ann. NY Acad. Sci. 2003. 987: 15-25.
23. + T cell-mediated suppression by dendritic cells. Science 2003. 299: 1033-1036.
24. Kemp, R. A. and Ronchese, F., Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity. J. Immunol. 2001. 167: 6497-6502.
25. Vegh, Z. and Mazumder, A., Generation of tumor cell lysate-loaded dendritic cells preprogrammed for IL-12 production and augmented T cell response. Cancer Immunol. Immunother 2003. 52: 67-79.
26. + and CD1a dendritic cell subsets differ in their cytokine production profiles, susceptibilities to transfection, and capacities to direct Th cell differentiation. J. Immunol. 2000. 165: 3584-3591.
27. Roncarolo, M. G., Levings, M. K. and Traversari, C., Differentiation of T regulatory cells by immature dendritic cells. J. Exp. Med. 2001. 193: F5-9.
28. Steinman, R. M., Turley, S., Mellman, I. and Inaba, K., The induction of tolerance by dendritic cells that have captured apoptotic cells. J. Exp. Med. 2000. 191: 411-416.
29. + regulatory T cells by antigen-processing dendritic cells. J. Exp. Med. 2003. 198: 235-247.
30. + T cell subset inhibits antigen-specific T cell responses and prevents colitis. Nature 1997. 389: 737-742.
31. Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny G. M., Nadaf, S., Kavanaugh, D. and Carbone, D. P., Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 1996. 2: 1096-1103.
32. Almand, B., Resser, J. R., Lindman, B., Nadaf, S., Clark, J. I., Kwon, E. D., Carbone, D. P. and Gabrilovich, D. I., Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res. 2000. 6: 1755-1766.
33. Ratta, M., Fagnoni, F., Curti, A., Vescovini, R., Sansoni, P., Oliviero, B., Fogli, M., Ferri, E., Della Cuna, G. R., Tura, S. et al., Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 2002. 100: 230-237.
34. Xie, J., Wang, Y., Freeman, M. E. 3rd, Barlogie, B. and Yi, Q., Beta 2-microglobulin as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cells. Blood 2003. 101: 4005-4012.
35. Hayashi, T., Hideshima, T., Akiyama, M., Raje, N., Richardson, P., Chauhan, D. and Anderson, K. C., Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. Blood 2003. 102: 1435-1442.
36. Dhodapkar, M. V., Krasovsky, J. and Olson, K., T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor specific cytolytic responses to autologous, tumor-loaded dendritic cells. Proc. Natl. Acad. Sci. USA 2002. 99: 13009-13013.
37. Wen, Y. J., Barlogie, B. and Yi, Q., Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. Blood 2001. 97: 1750-1755.
38. Li, Y., Bendandi, M., Deng, Y., Dunbar, C., Munshi, N., Jagannath, S., Kwak, L. W. and Lyerly, H. K., Tumor specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells. Blood 2000. 96: 2828-2833.
39. Wen, Y. J., Min, R., Tricot, G., Barlogie, B. and Yi, Q., Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood 2002. 99: 3280-3285.